Tagged with R&D

UK Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug discovery profile post-Brexit.  Could you please start by introducing the MDC? “We believe that the future is going to be…

Pharma While the automotive and electronics industries, among others, have been relatively fast in adopting robotics, pharma has been lagging behind. However, as the technology available becomes more advanced, flexible and affordable, robotics now stands as a pivotal element to helping pharmaceutical companies reduce costs and increase efficiency, notably in the…

Europe The top spenders on pharma R&D in Europe for 2015 were Switzerland – which spent over EUR 6.5 billion – followed by Germany – which spent EUR 6.2 billion – and the UK – which spent EUR 5.8 billion.

Spain Jose Escribano, founder of Spanish biotech success story ALGENEX, discusses the company’s focus on using insects in its research, difficulties in accessing capital, and its future growth strategy. Can you please start by describing the opportunities that presented themselves, allowing you to create ALGENEX? “What we have done is to…

China Guangdong province and neighbouring Hong Kong have long been fundamental to China’s metamorphosis into an economic superpower. Notable as one of the country’s most open and dynamic regions, the Pearl River Delta (PRD), as that area previously used to be known, historically formed the soft underbelly via which the outside…

China Shine Liu Xiancheng, CEO and founder of Lifotronic, discusses the rise of the medtech manufacturer over its ten years of existence, its commitment to R&D, and improving China’s innovation capacity.  Shine, as the founder and CEO of Lifotronic, let us start from the beginning of the story. What made you…

Portugal Paulo Teixeira shines a light on Pfizer’s promising pipeline for 2018, the market access environment in Portugal and the clinical trial landscape. Teixeira intends to contribute to improving society’s perception of the pharmaceutical industry and position Pfizer as a partner for health and wellbeing in Portugal; part of the solution—not…

UK Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance of vaccine R&D and production in the UK.   We have a broad portfolio, from the very first vaccine that…

UK Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and drive change by enhancing productivity. With positive evolutions in the UK government’s approach to collaborative partnerships, he warns that clarity…

R&D With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald a flurry of mergers and acquisitions (M&As) within the pharma world. “Biotech and pharma M&A activity dropped to its lowest…

Canada With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO Neil Closner also highlights MedReleaf’s important efforts in conducting R&D and clinical studies in order to present practitioners with relevant…

UK Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls for more creativity in HTA processses in a collaborative effort to bring innovation to patients faster. What is the scope…